The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC).
 
Omid Yazdanpanah
No Relationships to Disclose
 
David Joseph Benjamin
Consulting or Advisory Role - Seagen
 
Elham Vosoughi
No Relationships to Disclose
 
Ali Raad
No Relationships to Disclose
 
Medina Popal
No Relationships to Disclose
 
Piyanuch Kongtim
Research Funding - Eurofins Viracor
 
Nataliya Mar
Speakers' Bureau - Aveo; Eisai; Merck; Seagen; Tempus
Research Funding - Gilead Sciences
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; aveo; Bayer; Eisai; Exelixis
Speakers' Bureau - Amgen; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Myovant Sciences; Pfizer; Sanofi
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); navir (Inst); Novartis (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Janssen